| n | % |
---|---|---|
Radiotherapy completion | ||
Completed | 249 | 86.5 |
Discontinued | 39 | 13.5 |
Reason for discontinuation (n = 39) | ||
Death during radiotherapy | 19 | 48.7 |
Patient’s wish | 5 | 12.8 |
Worsening of general condition | 14 | 35.9 |
Unknown | 1 | 2.6 |
Localization (n = 516) | ||
Head-and-neck (w/o cervical spine) | 15 | 2.9 |
Spine | 254 | 49.2 |
Pelvis | 153 | 29.7 |
Thorax (w/o thoracic spine) | 37 | 7.2 |
Upper extremity | 28 | 5.4 |
Lower extremity | 29 | 5.6 |
SINS for spine metastases (n = 216)a | ||
0–6 (stable) | 102 | 47.2 |
7–12 (possibly impending) | 102 | 47.2 |
13–18 (unstable) | 12 | 5.6 |
Mizumoto score for spine metastases (n = 216)a | ||
0–4 | 140 | 64.8 |
5–9 | 74 | 34.3 |
10–14 | 2 | 0.9 |
Orthopedic corset | ||
No orthopedic corset | 258 | 89.6 |
Orthopedic corset | 30 | 10.4 |
Bone-modifying agents | ||
No bone-modifying agents | 161 | 55.9 |
Bisphosphonates | 105 | 36.5 |
Denosumab | 20 | 6.9 |
Unknown | 2 | 0.7 |
Systemic anti-cancer treatment | ||
No systemic treatment | 209 | 72.6 |
Systemic treatment | 77 | 26.7 |
Unknown | 2 | 0.7 |
 | Median | IQR |
---|---|---|
Radiotherapy fractionation (n = 516) | ||
Number of fractions | 12 | 10–14 |
Single dose [Gy] | 3 | 2.5–3 |
Total dose [Gy] | 35 | 30–35 |